TLDR
- Veeva Systems stock trades around $285, with analysts seeing up to 30% upside over the next 12 months.
- The company is migrating its core customer base off Salesforce and onto its native Veeva Vault CRM, with 14 of the top 20 global biopharmas already committed.
- Fiscal second-quarter revenue hit $928 million, up 18% year over year, with full-year guidance raised toward $3.7 billion.
- Veeva’s new Falcon platform uses agentic AI to automate tasks like medical and regulatory review, cutting manual work by up to 70%.
- Servier is rolling out Veeva OpenData across more than 80 countries to build a unified, AI-ready data foundation.
Veeva Systems stock closed at $285.45 on September 30, 2026. That’s well off its 2021 record high of $344, but some analysts think it has room to climb back there and beyond.
The company builds software for biotech and pharma clients. It handles everything from clinical trials to regulatory filings to day-to-day sales operations.
Veeva holds more than 80% market share in biopharma customer-relationship management software. That’s a dominant position in a niche most people have never heard of.
The Salesforce Breakup
Veeva’s software used to run on top of Salesforce. Since 2024, the company has been building its own replacement called Vault CRM and moving customers over.
The shift gives Veeva higher margins and full control of its own platform. It also frees the company from leaning on a competitor’s infrastructure.
So far, 14 of the 20 largest global biopharma companies have already committed to Vault CRM. That’s a strong signal the migration is working.
Wells Fargo analyst Stan Berenshteyn rates the stock Overweight with a $330 price target. He points to new CRM wins and growing traction in Veeva’s data cloud business as reasons to watch the stock.
Betting on Agentic AI
Veeva’s newest product line is called Falcon. It’s designed to handle multistep workflows with less human involvement.
One live example is Falcon MLR, which reviews promotional materials for medical, legal and regulatory compliance. More agents covering clinical, regulatory and safety work are planned through 2027.
Veeva estimates its tools could cut certain manual tasks by up to 70%. The company also says drug development timelines could speed up by 30% to 90% using its software.
Research firm Gartner projects global spending on task-specific AI agents will more than double every year through 2029. That’s a 119% compound annual growth rate, reaching over $750 billion.
Veeva reported fiscal second-quarter revenue of $928 million, up 18% from a year earlier. Adjusted earnings per share came in at $2.35, also up 18%.
The company raised its full-year revenue guidance toward $3.7 billion. That marks the third upward revision this year.
Full-year adjusted earnings per share guidance now sits near $9.21, up 14% from last year. Management is targeting a $6 billion annual revenue run rate by 2030.
That goal implies average annual growth of about 18% over the next three years. The target was first set in 2023, based on expected market share gains in Veeva’s core products.
The stock trades at about 27 times forward earnings. That’s pricier than the broader market and Salesforce’s 14 times multiple, but below Veeva’s own five-year average of 35 times.
Veeva’s operating margin consistently runs above 45%. Combined with revenue growth near 15%, that puts the company well past the software industry’s “Rule of 40” benchmark.
The company carries zero debt on its balance sheet. Risks include execution bumps during the ongoing Salesforce transition and shifting sentiment toward AI stocks generally.
On September 30, Veeva announced that French pharmaceutical company Servier is adopting Veeva OpenData globally. Servier will standardize customer reference data across more than 80 countries to build what it calls an AI-ready data foundation.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
